Clinical analysis of hematopoietic stem cell transplantation for the treatment of eld-erly myeloid tumors
10.12354/j.issn.1000-8179.2024.20240460
- VernacularTitle:造血干细胞移植治疗老年髓系肿瘤的临床分析
- Author:
Zheng YALING
1
;
Zheng ZIYU
;
Wu MING
;
Yang CHUTING
;
Huang RUI
;
Li YUHUA
Author Information
1. 南方医科大学附属珠江医院血液内科(广州市 510282)
- Keywords:
acute myeloid leukemia(AML);
myelodysplastic syndrome;
elderly;
hematopoietic stem cell transplantation(HSCT)
- From:
Chinese Journal of Clinical Oncology
2024;51(11):552-556
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of hematopoietic stem cell transplantationon(HSCT)survival outcomes in older patients with myeloid neoplasms.Methods:We retrospectively analyzed the treatment outcomes of 54 patients aged≥55 years with myeloid neoplasms who underwent HSCT between January 2018 and May 2023 at Zhujiang Hospital of Southern Medical University.Results:Among the 54 pa-tients,45 had acute myeloid leukemia(AML)and 9 had myelodysplastic syndrome.The median age of the patients was 57.5(55-68)years.Fifty-three patients underwent hematopoietic reconstitution,with a median time to neutrophil reconstitution of 13(8-24)days and median time to platelet reconstitution of 15(9-75)days.The cumulative incidence was 23.3%for acute graft-versus-host disease(GVHD)and 24.6%for 3-year chronic GVHD.With a median follow-up of 28.2 months,the 3-year cumulative relapse rate(CIR)was 18%and 3-year non-relapse mortality rate was 28.3%.The 3-year relapse-free survival(RFS)rate was 58.2%and 3-year overall survival(OS)rate was 56.5%.Conclu-sions:HSCT is an effective and safe therapy for achieving long-term survival in older patients with myeloid tumors.
